Literature DB >> 10073736

Comparison of urinary 6beta-hydroxycortisol/cortisol ratio between neonates and their mothers.

H Nakamura1, A Hasegawa, M Kimura, S Yamagata, H Nakasa, H Osada, S Sekiya, S Ohmori, M Kitada.   

Abstract

AIMS: To assess CYP3A enzyme activity in human neonates by measuring the urinary 6beta-hydroxycortisol/cortisol (6beta-OHF/C) ratio.
METHODS: Fifty-six mature male neonates with normal delivery, seventeen of their mothers and twenty-four healthy non-pregnant young women participated in this study. Urinary 6beta-OHF/C ratio was determined on the day of birth in neonates and their mothers. In addition, changes in the ratio after birth were determined in neonates.
RESULTS: On the day of birth, the urinary 6beta-OHF/C ratio of neonates was significantly higher than that of their mothers (20.5 vs 6.9). In contrast, no significant difference was observed in the mean ratio of urinary 6beta-OHF/C between women with and without pregnancy (6.9 vs 9.0). The urinary 6beta-OHF/C ratio after birth was decreased day by day in neonates.
CONCLUSION: These results indicate that the high urinary 6beta-OHF/C ratio in mature neonates on the day of birth is independent of the activity of CYP3A enzyme in their mothers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073736      PMCID: PMC2014205          DOI: 10.1046/j.1365-2125.1999.00857.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Isolation of a new human fetal liver cytochrome P450 cDNA clone: evidence for expression of a limited number of forms of cytochrome P450 in human fetal livers.

Authors:  M Komori; K Nishio; T Fujitani; H Ohi; M Kitada; S Mima; K Itahashi; T Kamataki
Journal:  Arch Biochem Biophys       Date:  1989-07       Impact factor: 4.013

2.  Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man.

Authors:  E E Ohnhaus; A M Breckenridge; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Molecular cloning and sequence analysis of cDNA containing the entire coding region for human fetal liver cytochrome P-450.

Authors:  M Komori; K Nishio; H Ohi; M Kitada; T Kamataki
Journal:  J Biochem       Date:  1989-02       Impact factor: 3.387

4.  Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase.

Authors:  P H Beaune; D R Umbenhauer; R W Bork; R S Lloyd; F P Guengerich
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

5.  The urinary 6 beta-hydroxycortisol excretion in man on inducers and inhibitors of the hepatic mixed function oxidase.

Authors:  J P Desager; E Dumont; C Harvengt
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

6.  Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.

Authors:  T Aoyama; S Yamano; D J Waxman; D P Lapenson; U A Meyer; V Fischer; R Tyndale; T Inaba; W Kalow; H V Gelboin
Journal:  J Biol Chem       Date:  1989-06-25       Impact factor: 5.157

7.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).

Authors:  S A Wrighton; W R Brian; M A Sari; M Iwasaki; F P Guengerich; J L Raucy; D T Molowa; M Vandenbranden
Journal:  Mol Pharmacol       Date:  1990-08       Impact factor: 4.436

8.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

Authors:  T Shimada; H Yamazaki; M Mimura; Y Inui; F P Guengerich
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

9.  Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver.

Authors:  J Hakkola; M Pasanen; R Purkunen; S Saarikoski; O Pelkonen; J Mäenpää; A Rane; H Raunio
Journal:  Biochem Pharmacol       Date:  1994-07-05       Impact factor: 5.858

10.  Identification of a polymorphically expressed member of the human cytochrome P-450III family.

Authors:  S A Wrighton; B J Ring; P B Watkins; M VandenBranden
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

View more
  4 in total

1.  Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol.

Authors:  Hanna Nylén; Sofia Sergel; Lisa Forsberg; Synnöve Lindemalm; Leif Bertilsson; Katarina Wide; Ulf Diczfalusy
Journal:  Eur J Clin Pharmacol       Date:  2011-01-19       Impact factor: 2.953

Review 2.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 3.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

Review 4.  A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates.

Authors:  Anne Smits; Pieter Annaert; Steven Van Cruchten; Karel Allegaert
Journal:  Front Pharmacol       Date:  2020-05-13       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.